# Ardelyx, Inc.

**ARDX**

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001437402

**A**

**strongest fifth of 305 graded peers in healthcare**

rank 47 of 305; percentile 15.1; sampling error 2.8 points; lower is stronger

A B C D E

**A, the bull**




| Scoreboard | |
|---|---|
| **Profitability** | B/C<br>percentile 42.2 |
| **Solvency** | C<br>percentile 45.7 |
| **Growth and financing** | A/B<br>percentile 18.1 |
| **Reliability** | 0.87 AUC<br>filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025 |
| **Peer failure rate** | 1.03% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $120M to $591M assets<br>total assets $501.6M |
| **Standard universe** | inside<br>revenue above $1M and assets above $10M |
| **Warnings** | none triggered<br>not computable: distress |
| **Inputs computable** | 8 of 13 |
| **Graded from** | filings received through Feb 19, 2026<br>276 days before the rescan; latest periodic filing 10-Q received Nov 3, 2026 |
| **Last close** | $2.99<br>2026-11-20; market equity $751.6M; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Feb 19, 2026*

We are a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. We currently market two therapies from the active ingredient tenapanor, a sodium/hydrogen exchanger (NHE3) inhibitor that was discovered and developed by Ardelyx. NHE3 is an antiporter expressed on the apical surface of the small and large intestines. Tenapanor is a minimally absorbed, first-in-class, oral, small molecule therapy. Tenapanor, branded as IBSRELA®, is approved in the U.S. for the treatment of adults with irritable bowel syndrome with constipation.

## The thirteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*


| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 42.2** | | | | | | |
| Gross profitability | 73.3% | 32.8% | | 11.3 | 346 | 2025-12-31 |
| Return on invested capital | not computable | 9.6% | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | |
|---|---|---|---|---|---|---|
| *pretax income must exceed the validity floor and imply a 0%-100% tax rate* | | | | | | |
| Accruals ratio | (4.1%) | (6.7%) | | 65.4 | 756 | 2025-12-31 |
| Gross margin stability, five years | 2.8 pts | 2.8 pts | | 50.0 | 237 | 2025-12-31 |
| **Solvency, sleeve percentile 45.7** | | | | | | |
| Altman Z double-prime | (2.34) | 0.31 | | 47.9 | 705 | 2025-12-31 |
| Net debt to EBITDA | not computable | 1.82x | | | | |
| *EBITDA must exceed $100,000* | | | | | | |
| Interest coverage | not computable | (3.61x) | | | | |
| *latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31* | | | | | | |
| Current ratio | 4.31x | 2.68x | | 43.6 | 781 | 2025-12-31 |
| **Growth and financing, sleeve percentile 18.1** | | | | | | |
| Revenue growth, three-year compound | 98.4% | 9.6% | | 5.8 | 400 | 2025-12-31 |
| Free cash flow growth, three-year compound | not computable | 11.1% | | | | |
| *current FCF must be positive and base FCF must exceed $100,000* | | | | | | |
| Reinvestment rate | not computable | 33.9% | | | | |
| *pretax income must exceed the validity floor and imply a 0%-100% tax rate* | | | | | | |
| Asset growth, three years | 38.2% | 3.2% | | 11.3 | 663 | 2025-12-31 |
| Net share issuance, one year | 2.9% | 1.6% | | 37.1 | 626 | 2026-02-12 |

## Among 305 peers

*healthcare; letters are fifths of this list*




*Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.*

| Rank | Company | Percentile | Letter | Warnings |
|---|---|---|---|---|
| 42 | Utah Medical Products Inc. (UTMD) | 13.5 | A | fortress balance sheet |
| 43 | Procept BioRobotics Corp. (PRCT) | 13.8 | A | fortress balance sheet |
| 44 | Resmed Inc. (RMD) | 14.1 | A | fortress balance sheet |
| 45 | PRO DEX Inc. (PDEX) | 14.5 | A | |
| 46 | Insulet Corp. (PODD) | 14.8 | A | |
| 47 | Ardelyx, Inc. (ARDX) | 15.1 | A | |
| 48 | Lantheus Holdings, Inc. (LNTH) | 15.5 | A | |
| 49 | Harrow, Inc. (HROW) | 15.8 | A | late filer |
| 50 | TG Therapeutics, Inc. (TGTX) | 16.1 | A | |
| 51 | Natures Sunshine Products Inc. (NATR) | 16.4 | A | fortress balance sheet |
| 52 | Alnylam Pharmaceuticals, Inc. (ALNY) | 16.8 | A | |

## What the price implies

*at the 2026-11-20 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | (43.6%) | (1.7%) | 19 |
| Distance from 52-week high | (62.6%) | (33.0%) | 23 |
| EBIT to enterprise value | (4.3%) | 0.5% | 38 |
| Free cash flow yield | (5.9%) | 0.6% | 33 |
| Book value to price | 0.22 | 0.29 | 42 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | |
|---|---|---|---|
| Sales to price | 0.54 | 0.38 | 62 |
| Composite equity issuance, five years | 93.5% | 13.5% | 82 |
| Relative strength against the sector, log excess return | (0.74) | (0.19) | 19 |
| Twelve-month failure probability, CHS model | not computable | 0.06% | |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score 2 of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |
| Return on assets improved | fail |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | fail |
| Current ratio improved | fail |
| No new shares issued | fail |
| Gross margin improved | pass |
| Asset turnover improved | fail |
| **Cash, filings, liquidity** | |
| Cash and equivalents | $46.3M |
| Operating cash flow, four quarters | -$15.5M |
| Months of runway | 35.8 |
| Days since last periodic filing | 19 (10-Q received Nov 3, 2026) |
| Median daily dollar volume, 63 sessions | $14.4M |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $407.3M | 2025-12-31 | 2026-02-19 | 10-K | 26-000013 |
| 2 | cost of revenue | us-gaap:CostOfGoodsAndServicesSold | $39.5M | 2025-12-31 | 2026-02-19 | 10-K | 26-000013 |
| 3 | assets | us-gaap:Assets | $501.6M | 2025-12-31 | 2026-02-19 | 10-K | 26-000013 |
| 4 | operating income | us-gaap:OperatingIncomeLoss | -$41.0M | 2025-12-31 | 2026-02-19 | 10-K | 26-000013 |
| 5 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | -$60.6M | 2025-12-31 | 2026-02-19 | 10-K | 26-000013 |
| 6 | income tax | us-gaap:IncomeTaxExpenseBenefit | $969,000 | 2025-12-31 | 2026-02-19 | 10-K | 26-000013 |
| 7 | total debt | us-gaap:LongTermDebt | $202.8M | 2025-12-31 | 2026-02-19 | 10-K | 26-000013 |
| 8 | book equity | us-gaap:StockholdersEquity | $166.9M | 2025-12-31 | 2026-02-19 | 10-K | 26-000013 |
| 9 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $68.0M | 2025-12-31 | 2026-02-19 | 10-K | 26-000013 |
| 10 | total debt | us-gaap:LongTermDebt | $150.9M | 2024-12-31 | 2026-02-19 | 10-K | 26-000013 |
| 11 | book equity | us-gaap:StockholdersEquity | $173.3M | 2024-12-31 | 2026-02-19 | 10-K | 26-000013 |
| 12 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $64.9M | 2024-12-31 | 2026-02-19 | 10-K | 26-000013 |
| 13 | net income | us-gaap:NetIncomeLoss | -$61.6M | 2025-12-31 | 2026-02-19 | 10-K | 26-000013 |
| 14 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$42.5M | 2025-12-31 | 2026-02-19 | 10-K | 26-000013 |
| 15 | assets | us-gaap:Assets | $435.8M | 2024-12-31 | 2026-02-19 | 10-K | 26-000013 |
| 16 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $333.6M | 2024-12-31 | 2026-02-19 | 10-K | 26-000013 |
| 17 | cost of revenue | us-gaap:CostOfGoodsAndServicesSold | $50.6M | 2024-12-31 | 2026-02-19 | 10-K | 26-000013 |
| 18 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $124.5M | 2023-12-31 | 2026-02-19 | 10-K | 26-000013 |
| 19 | cost of revenue | us-gaap:CostOfGoodsAndServicesSold | $17.8M | 2023-12-31 | 2026-02-19 | 10-K | 26-000013 |
| 20 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $52.2M | 2022-12-31 | 2025-02-20 | 10-K | 25-006653 |
| 21 | cost of revenue | us-gaap:CostOfRevenue | $4.1M | 2022-12-31 | 2023-03-02 | 10-K | 23-006041 |
| 22 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $10.1M | 2021-12-31 | 2024-02-22 | 10-K | 24-006393 |
| 23 | cost of revenue | us-gaap:CostOfRevenue | $1.0M | 2021-12-31 | 2023-03-02 | 10-K | 23-006041 |
| 24 | current assets | us-gaap:AssetsCurrent | $382.3M | 2025-12-31 | 2026-02-19 | 10-K | 26-000013 |
| 25 | current liabilities | us-gaap:LiabilitiesCurrent | $88.6M | 2025-12-31 | 2026-02-19 | 10-K | 26-000013 |
| 26 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$946.9M | 2025-12-31 | 2026-02-19 | 10-K | 26-000013 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| 27 | liabilities | us-gaap:Liabilities | $334.7M | 2025-12-31 | 2026-02-19 | 10-K | 26-000013 |
| 28 | depreciation amortization | us-gaap:DepreciationDepletionAndAmortization | $3.1M | 2025-12-31 | 2026-02-19 | 10-K | 26-000013 |
| 29 | operating income | us-gaap:OperatingIncomeLoss | -$63.3M | 2023-12-31 | 2026-02-19 | 10-K | 26-000013 |
| 30 | interest expense | us-gaap:InterestExpense | $5.0M | 2023-12-31 | 2024-02-22 | 10-K | 24-006393 |
| 31 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $1.5M | 2025-12-31 | 2026-02-19 | 10-K | 26-000013 |
| 32 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$44.8M | 2024-12-31 | 2026-02-19 | 10-K | 26-000013 |
| 33 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $1.0M | 2024-12-31 | 2026-02-19 | 10-K | 26-000013 |
| 34 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$89.7M | 2023-12-31 | 2026-02-19 | 10-K | 26-000013 |
| 35 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $344,000 | 2023-12-31 | 2026-02-19 | 10-K | 26-000013 |
| 36 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$70.0M | 2022-12-31 | 2025-02-20 | 10-K | 25-006653 |
| 37 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $55,000 | 2022-12-31 | 2025-02-20 | 10-K | 25-006653 |
| 38 | current assets | us-gaap:AssetsCurrent | $356.5M | 2024-12-31 | 2026-02-19 | 10-K | 26-000013 |
| 39 | current liabilities | us-gaap:LiabilitiesCurrent | $77.8M | 2024-12-31 | 2026-02-19 | 10-K | 26-000013 |
| 40 | assets | us-gaap:Assets | $297.6M | 2023-12-31 | 2025-02-20 | 10-K | 25-006653 |
| 41 | assets | us-gaap:Assets | $190.1M | 2022-12-31 | 2024-02-22 | 10-K | 24-006393 |
| 42 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 245,247,427 | 2026-02-12 | 2026-02-19 | 10-K | 26-000013 |
| 43 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 238,356,222 | 2025-02-14 | 2025-02-20 | 10-K | 25-006653 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.